High-fat diet-induced changes in liver thioredoxin and thioredoxin reductase as a novel feature of insulin resistance

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 928-935

  Qin, Huijun ^a   Zhang, Xiaolin ^b   Ye, Fei ^b   Zhong, Liangwei ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

High fat diet; Insulin resistance; S acylation; Thioredoxin; Thioredoxin reductase

Indexed keywords

THIOREDOXIN; THIOREDOXIN REDUCTASE; 4 HYDROXYNONENAL; INSULIN; LIVER ENZYME;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID OXIDATION; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; LIVER; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UREA CYCLE; ACYLATION; BLOOD SAMPLING; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION;

EID: 84918521580     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2014.10.015     Document Type: Article

References (37)

1. Vial G., et al. Effects of a high-fat diet on energy metabolism and ROS production in rat liver. J. Hepatol. 2011, 54:348-356.
2. Matsuzawa-Nagata N., et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 2008, 57:1071-1077.
3. Zhong L., Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J. Biol. Chem. 2000, 275:18121-18128.
4. Bjornstedt M., Xue J., Huang W., Akesson B., Holmgren A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. J. Biol. Chem. 1994, 269:29382-29384.
5. Cha M.K., Kim I.H. Thioredoxin-linked peroxidase from human red blood cell: evidence for the existence of thioredoxin and thioredoxin reductase in human red blood cell. Biochem. Biophys. Res. Commun. 1995, 217:900-907.
6. Saitoh M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596-2606.
7. Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J. Biol. Chem. 1979, 254:9627-9632.
8. Sengupta R., Holmgren A. The role of thioredoxin in the regulation of cellular processes by S-nitrosylation. Biochim. Biophys. Acta 2012, 1820:689-700.
9. Chen Y.Y., Chu H.M., Pan K.T., Teng C.H., Wang D.L., Wang A.H., Khoo K.H., Meng T.C. Cysteine S-nitrosylation protects protein-tyrosine phosphatase 1B against oxidation-induced permanent inactivation. J. Biol. Chem. 2008, 283:35265-35272.
10. Ovadia H., Haim Y., Nov O., Almog O., Kovsan J., Bashan N., Benhar M., Rudich A. Increased adipocyte S-nitrosylation targets anti-lipolytic action of insulin: relevance to adipose tissue dysfunction in obesity. J. Biol. Chem. 2011, 286:30433-30443.
11. Mueller A.S., et al. Redox regulation of protein tyrosine phosphatase 1B by manipulation of dietary selenium affects the triglyceride concentration in rat liver. J. Nutr. 2008, 138:2328-2336.
12. Kakisaka Y., Nakashima T., Sumida Y., Yoh T., Nakamura H., Yodoi J., Senmaru H. Elevation of serum thioredoxin levels in patients with type 2 diabetes. Horm. Metab. Res. 2002, 34:160-164.
13. Henriksen E.J., Diamond-Stanic M.K., Marchionne E.M. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic. Biol. Med. 2011, 51:993-999.
14. Videla L.A. Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World J. Hepatol. 2009, 1:72-78.
15. Bugianesi E., Moscatiello S., Ciaravella M.F., Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr. Pharm. Des. 2010, 16:1941-1951.
16. Wu Y., Yang L., Zhong L. Decreased serum levels of thioredoxin in patients with coronary artery disease plus hyperhomocysteinemia is strongly associated with the disease severity. Atherosclerosis 2010, 212:351-355.
17. Drisdel R.C., Green W.N. Labeling and quantifying sites of protein palmitoylation. Biotechniques 2004, 36:276-285.
18. Cebula M., Moolla N., Capovilla A., Arner E.S. The rare TXNRD1_v3 ("v3") splice variant of human thioredoxin reductase 1 protein is targeted to membrane rafts by N-acylation and induces filopodia independently of its redox active site integrity. J. Biol. Chem. 2013, 288:10002-10011.
19. Linder M.E., Deschenes R.J. Palmitoylation: policing protein stability and traffic. Nat. Rev. Mol. Cell Biol. 2007, 8:74-84.
20. Shinkai Y., Iwamoto N., Miura T., Ishii T., Cho A.K., Kumagai Y. Redox cycling of 1,2-naphthoquinone by thioredoxin1 through Cys32 and Cys35 causes inhibition of its catalytic activity and activation of ASK1/p38 signaling. Chem. Res. Toxicol. 2012, 25:1222-1230.
21. Wei Y., Wang D., Topczewski F., Pagliassotti M.J. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 2006, 291:275-281.
22. Nemanich S., Rani S., Shoghi K. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-gamma therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats. Obesity (Silver Spring) 2013, 21:2522-2529.
23. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53(Suppl 1):43-50.
24. Zhou Y., Jia X., Wang G., Wang X., Liu J. PI-3 K/AKT and ERK signaling pathways mediate leptin-induced inhibition of PPARgamma gene expression in primary rat hepatic stellate cells. Mol. Cell. Biochem. 2009, 325:131-139.
25. Swarbrick M.M., et al. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology 2009, 150:1670-1679.
26. Ortmeyer H.K., et al. Insulin signaling and insulin sensitizing in muscle and liver of obese monkeys: peroxisome proliferator-activated receptor gamma agonist improves defective activation of atypical protein kinase C. Antioxid. Redox Signal. 2011, 14:207-219.
27. Lu M., et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 2012, 18:388-395.
28. Paramio J.M., Segrelles C., Ruiz S., Jorcano J.L. Inhibition of protein kinase B (PKB) and PKCzeta mediates keratin K10-induced cell cycle arrest. Mol. Cell. Biol. 2001, 21:7449-7459.
29. Dube N., Tremblay M.L. Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim. Biophys. Acta 2005, 1754:108-117.
30. Calera M.R., Vallega G., Pilch P.F. Dynamics of protein-tyrosine phosphatases in rat adipocytes. J. Biol. Chem. 2000, 275:6308-6312.
31. Kerouz N.J., Horsch D., Pons S., Kahn C.R. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest. 1997, 100:3164-3172.
32. Matsumoto M., Ogawa W., Teshigawara K., Inoue H., Miyake K., Sakaue H., Kasuga M. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes. Diabetes 2002, 51:1672-1680.
33. Matsumoto M., Han S., Kitamura T., Accili D. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 2006, 116:2464-2472.
34. Fang J., Holmgren A. Inhibition of thioredoxin and thioredoxin reductase by 4-hydroxy-2-nonenal in vitro and in vivo. J. Am. Chem. Soc. 2006, 128:1879-1885.
35. Bruns C.M., Hubatsch I., Ridderstrom M., Mannervik B., Tainer J.A. Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products. J. Mol. Biol. 1999, 288:427-439.
36. Sheridan A.M., Fitzpatrick S., Wang C., Wheeler D.C., Lieberthal W. Lipid peroxidation contributes to hydrogen peroxide induced cytotoxicity in renal epithelial cells. Kidney Int. 1996, 49:88-93.
37. Arner E.S., Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 2000, 267:6102-6109.